Treating eosinophilic exacerbations of asthma and COPD with benralizumab (ABRA): a double-blind, double-dummy, active placebo-controlled randomised trial

Ramakrishnan S., Russell REK., Mahmood HR., Krassowska K., Melhorn J., Mwasuku C., Pavord ID., Bermejo-Sanchez L., Howell I., Mahdi M., Peterson S., Bengtsson T., Bafadhel M.

DOI

10.1016/s2213-2600(24)00299-6

Type

Journal article

Journal

The Lancet Respiratory Medicine

Publisher

Elsevier BV

Publication Date

01/2025

Volume

13

Pages

59 - 68

Permalink Original publication